QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)
QQQ   296.26 (+1.00%)
AAPL   145.93 (+1.37%)
MSFT   248.16 (+0.06%)
META   151.74 (+3.01%)
GOOGL   99.37 (+1.90%)
AMZN   102.24 (+3.04%)
TSLA   177.90 (+11.00%)
NVDA   203.65 (+2.84%)
NIO   12.71 (+4.44%)
BABA   118.38 (-1.82%)
AMD   75.40 (+0.32%)
T   19.95 (-0.25%)
MU   63.87 (+1.70%)
F   13.27 (+2.71%)
CGC   2.93 (+6.16%)
GE   83.23 (+2.58%)
DIS   109.54 (-0.15%)
AMC   5.51 (+4.36%)
PFE   43.79 (-1.04%)
PYPL   81.83 (+1.26%)
NFLX   360.77 (-1.12%)

Invitae - NVTA Stock Forecast, Price & News

$2.54
+0.08 (+3.25%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.41
$2.62
50-Day Range
$1.71
$2.97
52-Week Range
$1.67
$12.04
Volume
8.20 million shs
Average Volume
8.01 million shs
Market Capitalization
$616.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.04

Invitae MarketRank™ Forecast

Analyst Rating
Hold
1.75 Rating Score
Upside/​Downside
216.6% Upside
$8.04 Price Target
Short Interest
Healthy
17.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.16
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$114,644 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.42) to ($1.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

365th out of 1,055 stocks

Medical Laboratories Industry

11th out of 25 stocks


NVTA stock logo

About Invitae (NYSE:NVTA) Stock

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Stock News Headlines

Invitae Reports Preliminary 2022 Financial Results
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Is Invitae in Danger of Running Out of Money?
Why Shares of Invitae Rose 11% on Tuesday
Why Invitae Stock Is Crushing It Today
Invitae (NVTA) Q3 2022 Earnings Call Transcript
Is Invitae Stock a Buy Now?
Invitae (NYSE: NVTA) Share Price and News
Why Invitae Stock Is Jumping Today
See More Headlines
Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Company Calendar

Last Earnings
11/08/2022
Today
1/27/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
3,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$8.04
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$2.80
Forecasted Upside/Downside
+216.6%
Consensus Rating
Hold
Rating Score (0-4)
1.75
Research Coverage
12 Analysts

Profitability

Net Income
$-379,010,000.00
Net Margins
-617.65%
Pretax Margin
-626.73%

Debt

Sales & Book Value

Annual Sales
$460.45 million
Book Value
$13.16 per share

Miscellaneous

Free Float
240,224,000
Market Cap
$616.96 million
Optionable
Optionable
Beta
1.72

Key Executives

  • Kenneth D. Knight
    Chief Executive Officer & Director
  • Roxi Wen
    Chief Financial Officer
  • Robert L. NussbaumRobert L. Nussbaum
    Chief Medical Officer
  • Karthik Suri
    Chief Product & Technology Officer
  • Eric Olivares
    Chief Science Officer













NVTA Stock - Frequently Asked Questions

Should I buy or sell Invitae stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 3 sell ratings and 9 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" NVTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares.
View NVTA analyst ratings
or view top-rated stocks.

What is Invitae's stock price forecast for 2023?

12 Wall Street research analysts have issued twelve-month price objectives for Invitae's stock. Their NVTA share price forecasts range from $2.80 to $18.00. On average, they anticipate the company's stock price to reach $8.04 in the next twelve months. This suggests a possible upside of 211.7% from the stock's current price.
View analysts price targets for NVTA
or view top-rated stocks among Wall Street analysts.

How have NVTA shares performed in 2023?

Invitae's stock was trading at $1.86 at the beginning of the year. Since then, NVTA stock has increased by 38.7% and is now trading at $2.58.
View the best growth stocks for 2023 here
.

When is Invitae's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our NVTA earnings forecast
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) announced its quarterly earnings data on Tuesday, November, 8th. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.17. The medical research company earned $133.54 million during the quarter, compared to the consensus estimate of $132.80 million. Invitae had a negative net margin of 617.65% and a negative trailing twelve-month return on equity of 39.04%.

What guidance has Invitae issued on next quarter's earnings?

Invitae updated its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $122.00 million-$122.00 million, compared to the consensus revenue estimate of $121.46 million.

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by many different retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (11.15%), Bourne Lent Asset Management Inc. (0.08%), Green Alpha Advisors LLC (0.06%), Profit Investment Management LLC (0.02%), Cyndeo Wealth Partners LLC (0.01%) and Foundations Investment Advisors LLC (0.01%). Insiders that own company stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen.
View institutional ownership trends
.

How do I buy shares of Invitae?

Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $2.58.

How much money does Invitae make?

Invitae (NYSE:NVTA) has a market capitalization of $626.67 million and generates $460.45 million in revenue each year. The medical research company earns $-379,010,000.00 in net income (profit) each year or ($13.84) on an earnings per share basis.

How many employees does Invitae have?

The company employs 3,000 workers across the globe.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (628) 213-3369 or via email at ir@invitae.com.

This page (NYSE:NVTA) was last updated on 1/27/2023 by MarketBeat.com Staff